Immuron Stock

Immuron EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Immuron (IMC.AX) as of Jul 15, 2026 is -1.71. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.74 — a change of -2.11% (higher).

EV/EBIT

-1.71

YoY

-2.11%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Immuron is 2026 -1.71 . EV/EBIT (Enterprise Value to EBIT) of Immuron was 2025 -1.74 . It decreases by -2.11% higher compared to the previous year.

The Immuron EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-9.45 base
Jan 1, 2019
-4.01 base
Jan 1, 2020
-13.21 base
Jan 1, 2021
-3.07 base
Jan 1, 2022
-6.28 base
Jan 1, 2023
-5.10 base
Jan 1, 2024
-3.43 base
Jan 1, 2025
-1.55 base
YEARPRICE-TO-EBIT
2025 -1.55
2024 -3.43
2023 -5.10
2022 -6.28
2021 -3.07
2020 -13.21
2019 -4.01
2018 -9.45
2017 -3.03
2016 -3.93
2015 -10.76
2014 -3.76
2013 -1.72
2012 -1.52
2011 -6.30
2010 -8.96
2009 -4.94
2008 -1.10
2007 -3.09
2006 -9.39
Access this data via the Eulerpool API

Immuron Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Immuron's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Immuron's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Immuron's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Immuron grows earnings faster than its peers.

Immuron Stock analysis

What does Immuron do? Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immuron stock

EV/EBIT (Enterprise Value to EBIT) of Immuron is -1.71 in 2026.

Access this data via the Eulerpool API

Valuation — Immuron

All Key Metrics — Immuron